Immunovant, Inc. (NASDAQ:IMVT) ranks among the best short squeeze stocks to buy right now. Following the company’s fiscal second-quarter 2026 financial results, Oppenheimer reaffirmed its Outperform rating on Immunovant, Inc. (NASDAQ:IMVT) on November 11 with a price target of $54. The company’s reported earnings per share of -$0.73 fell short of the -$0.71 consensus estimate. With $4.4 billion in cash and no debt on its balance sheet, Immunovant, Inc. maintains a strong capital position in despite these deficits.
Source: Pixabay
The company intends to publish results from a proof-of-concept study in cutaneous lupus and preliminary clinical data for IMVT-1402 in ACPA+ difficult-to-treat rheumatoid arthritis in 2026. According to Oppenheimer, the medication is “positioned as best-in-class” and has “considerable upside” as it moves closer to possible commercialization across multiple indications.
Immunovant, Inc. is also testing a second drug candidate, batoclimab, in mid-late-stage trials for two separate autoimmune conditions: GD and thyroid eye disease (TED).
Immunovant, Inc. is a clinical-stage immunology company focused on developing innovative therapies for autoimmune diseases. The company’s primary focus is on creating anti-FcRn (neonatal Fc receptor) antibodies which aim to reduce harmful immunoglobulin G (IgG) autoantibodies in patients with various autoimmune conditions.
READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.
This article is originally published at Insider Monkey.
